|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
1998-6-15
|
|
pubmed:abstractText |
About 50% of septic shock cases are attributed to Gram-negative bacteria or their cell wall compound lipopolysaccharide (LPS, endotoxin). An attractive therapeutic strategy could target the binding of LPS to its cellular receptors. In vitro the soluble form of the endotoxin receptor CD14 (sCD14) competitively prevents binding of LPS to membrane-bound CD14 and inhibits LPS-stimulated macrophage responses.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0014-2972
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
28
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
205-13
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:9568466-Animals,
pubmed-meshheading:9568466-Antigens, CD14,
pubmed-meshheading:9568466-CHO Cells,
pubmed-meshheading:9568466-Cricetinae,
pubmed-meshheading:9568466-Disease Models, Animal,
pubmed-meshheading:9568466-Female,
pubmed-meshheading:9568466-Humans,
pubmed-meshheading:9568466-Interferon-gamma,
pubmed-meshheading:9568466-Interleukin-6,
pubmed-meshheading:9568466-Kupffer Cells,
pubmed-meshheading:9568466-Lipopolysaccharides,
pubmed-meshheading:9568466-Macrophages,
pubmed-meshheading:9568466-Male,
pubmed-meshheading:9568466-Mice,
pubmed-meshheading:9568466-Mice, Inbred BALB C,
pubmed-meshheading:9568466-Recombinant Proteins,
pubmed-meshheading:9568466-Shock, Septic,
pubmed-meshheading:9568466-Solubility,
pubmed-meshheading:9568466-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Different efficacy of soluble CD14 treatment in high- and low-dose LPS models.
|
|
pubmed:affiliation |
Ernst-Moritz-Arndt-University, Greifswald, Germany.
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|
